Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

July 20, 2023

Study Completion Date

July 20, 2023

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK3923868

GSK3923868 will be administered

DRUG

Placebo

Placebo will be administered

Trial Locations (1)

GSK Investigational Site, Berlin